BioNTech's Personalized mRNA Vaccine Keeps 11 of 14 Triple-Negative Breast Cancer Patients Relapse-Free for Up to Six Years
A first-in-human trial published in Nature shows BioNTech's individualized neoantigen mRNA vaccine produces durable T cell immunity and sustained disease control in aggressive breast cancer.
Overview
A first-in-human clinical trial of BioNTech’s personalized mRNA cancer vaccine has demonstrated that individualized neoantigen immunization can produce durable T cell responses and sustained disease control in patients with triple-negative breast cancer (TNBC), one of the most aggressive and difficult-to-treat forms of the disease. The results, published in Nature, show that 11 of 14 vaccinated patients remained relapse-free for up to six years after treatment, a striking outcome in a cancer subtype where early recurrence is common.
The study, known as TNBC-MERIT (Mutanome Engineered RNA Immuno-Therapy), was conducted by researchers at BioNTech, TRON (Translational Oncology at the University Medical Centre of the Johannes Gutenberg University), and multiple European medical institutions, with Ugur Sahin and Mathias Schmidt serving as co-lead authors.
What We Know
Triple-negative breast cancer accounts for roughly 15 percent of all breast cancer diagnoses and lacks the estrogen, progesterone, and HER2 receptors that make other breast cancers treatable with targeted therapies. Patients face a high risk of early recurrence, particularly within the first three years after diagnosis, according to Nature’s coverage of the study.
The TNBC-MERIT trial enrolled 14 patients with early-stage TNBC within one year of completing standard surgery and chemotherapy. Each patient received a personalized vaccine encoding up to 20 tumor-specific neoantigens — mutations unique to their individual tumors — identified through next-generation sequencing of resected tissue. The neoantigens were encoded on two RNA-lipoplex mRNA molecules formulated in liposomal nanoparticles for intravenous administration. Patients received eight intravenous doses over nine weeks: six weekly and two biweekly, as described in the study.
All 14 patients generated vaccine-induced T cell responses against at least one personalized neoantigen, and nine developed responses targeting five or more neoantigens. The induced CD8+ T cells reached frequencies of up to 17.5 percent of circulating CD8+ T cells — levels more commonly associated with adoptive cell therapies — and remained functionally active for years without booster vaccination, according to the Nature study.
A substantial proportion of the vaccine-induced T cells developed into two distinct phenotypes: late-differentiated cytotoxic effector cells described as “ready-to-act,” and stem cell-like memory T cells that could sustain long-term immune surveillance. After a median follow-up of 62 months, 10 of 14 patients remained relapse-free, with one additional patient remaining relapse-free until death from an unrelated cause, according to PubMed records of the study.
Of the three patients who did relapse, each case offered distinct immunological insights: one had the weakest vaccine-induced T cell response but subsequently achieved complete remission on anti-PD-1 checkpoint inhibitor therapy; another had a tumor with low MHC class I expression, an immune escape mechanism that prevented T cell recognition; and the third was BRCA-positive with a recurrence originating from a genetically distinct contralateral tumor, as reported in Nature.
This work builds on the broader momentum in personalized mRNA cancer vaccines. As previously reported, Moderna and Merck’s individualized neoantigen vaccine demonstrated a sustained 49 percent reduction in melanoma recurrence at five years in the larger KEYNOTE-942 trial. The BioNTech TNBC-MERIT results now extend the evidence for personalized mRNA vaccines to a second major cancer type with similarly durable outcomes, albeit in a smaller exploratory cohort.
What We Don’t Know
The trial’s primary limitation is its small size — 14 patients with no control group — making it impossible to draw definitive conclusions about the vaccine’s efficacy compared to standard care alone. While the relapse-free rate is encouraging, it cannot be statistically separated from natural variation in outcomes without a randomized controlled study.
It remains unclear whether the approach can scale. Manufacturing a personalized vaccine for each patient requires tumor sequencing, neoantigen selection, and custom mRNA synthesis — a process that is time-intensive and expensive. How quickly BioNTech can manufacture these vaccines at clinical scale, and at what cost, will be critical factors in determining broader applicability.
The immune escape observed in the MHC class I-deficient relapse case also raises questions about whether combination strategies — pairing the vaccine with checkpoint inhibitors or other immunotherapies from the outset — might be necessary for a subset of patients.
Multiple Phase II trials are underway to test the personalized vaccine approach against standard treatments in larger cohorts, according to Nature. Results from these studies will be essential to establish whether the durable immune responses observed in this small exploratory trial translate into meaningful clinical benefit at scale.